Anika Therapeutics Organic Growth Can’t Offset Viscosupplement Declines

Anika Therapeutics' logo

Anika Therapeutics reported 1Q21 orthopedic revenue of USD $31.5 million, -5.5% vs. 1Q20. COVID-related headwinds and inventory stocking declines in orthobiologics offset revenue increases from the acquisitions of Parcus and Arthrosurface.

Joint replacement and sports medicine sales growth meaningfully shifted Anika’s overall product mix....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us